Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CFO Richard Pulik sold 406,731 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the completion of the sale, the chief financial officer directly owned 239,413 shares of the company’s stock, valued at approximately $5,370,033.59. The trade was a 62.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Roivant Sciences Price Performance

ROIV stock traded down $0.53 during mid-day trading on Monday, reaching $21.70. The company had a trading volume of 5,266,402 shares, compared to its average volume of 8,130,591. The company has a market capitalization of $15.09 billion, a PE ratio of -38.75 and a beta of 1.22. The firm has a 50 day moving average of $20.65 and a 200 day moving average of $15.59. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $23.47.

Institutional Trading of Roivant Sciences

Several large investors have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new position in shares of Roivant Sciences in the 2nd quarter worth approximately $37,546,000. Marshall Wace LLP lifted its stake in Roivant Sciences by 316.5% during the third quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock worth $60,187,000 after purchasing an additional 3,022,851 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Roivant Sciences during the second quarter worth $31,324,000. Rubric Capital Management LP boosted its position in shares of Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Roivant Sciences in the third quarter valued at $34,513,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ROIV shares. Bank of America lifted their price target on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. Leerink Partners boosted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. The Goldman Sachs Group increased their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Finally, Citigroup raised their target price on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.